GlaxoSmithKline's approval streak helps ease scandal pain

GlaxoSmithKline ($GSK) has been having a year for the record book. And that's not entirely a good thing. Report

Suggested Articles

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.